FDA recall record

Boehringer Ingelheim Roxane Pradaxa (dabigatran etexilate), 75 mg Capsules, 60 count bottles recall — FDA D-067-2013

Defective container; damaged bottles could allow moisture to get into the bottle and thus may impair the quality of the product

Class IIclassification
D-067-2013official record ID
Dec 5, 2012report date

Recall record at a glance

Official recordD-067-2013
CategoryDrug Recalls
ClassificationClass II
FDA record statusTerminated
Recalling firmBoehringer Ingelheim Roxane Inc.
Report dateDec 5, 2012
Recall initiation dateNov 5, 2012
Quantity8,381 bottles
LocationColumbus, OH, United States

Official product description

Pradaxa (dabigatran etexilate), 75 mg Capsules, 60 count bottles, Rx only, Distributed by Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT --- NDC 0597-0149-54

Why the product was recalled

Defective container; damaged bottles could allow moisture to get into the bottle and thus may impair the quality of the product

Distribution information

Nationwide

How to read the classification

FDA Class II indicates a situation in which use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious consequences is remote. The classification shown here comes from the FDA record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.

Related recall records

Other records from the same recalling company are shown first when available.

DrugAug 5, 2015

COMBIVENT RESPIMAT recall — FDA D-1279-2015

Defective Delivery System: Inhalers do not spray properly, emitting either no spray or a short transient spray.

Class IIFDA: TerminatedBoehringer Ingelheim Roxane Inc.